Titan Pharmaceuticals (TTNP) to Release Quarterly Earnings on Wednesday

Titan Pharmaceuticals (NASDAQ:TTNP) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 15th.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Monday, April 1st. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.20). Titan Pharmaceuticals had a negative net margin of 136.32% and a negative return on equity of 355.20%. The company had revenue of $1.24 million during the quarter, compared to the consensus estimate of $0.40 million. On average, analysts expect Titan Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ TTNP traded up $0.01 during trading on Thursday, hitting $1.65. The company’s stock had a trading volume of 65,400 shares, compared to its average volume of 991,374. The company has a quick ratio of 3.49, a current ratio of 3.85 and a debt-to-equity ratio of 0.55. The company has a market cap of $22.25 million, a P/E ratio of -2.09 and a beta of 0.67. Titan Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $6.90.

Separately, ValuEngine raised Titan Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd.

A hedge fund recently raised its stake in Titan Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by 256.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 341,474 shares of the specialty pharmaceutical company’s stock after buying an additional 245,565 shares during the period. Geode Capital Management LLC owned approximately 2.63% of Titan Pharmaceuticals worth $76,000 as of its most recent SEC filing. 24.17% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Titan Pharmaceuticals (TTNP) to Release Quarterly Earnings on Wednesday” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2019/05/09/titan-pharmaceuticals-ttnp-to-release-quarterly-earnings-on-wednesday.html.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

See Also: What is the Fibonacci sequence?

Earnings History for Titan Pharmaceuticals (NASDAQ:TTNP)

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply